Adult acne in women is one of the most frustrating skin pathologies, not least because it is so poorly understood by the people experiencing it. For many women, even after adolescence, who eat reasonably well and wash their faces, the breakouts keep coming. They arrive on the jaw, the chin, the lower cheeks, and they tend to cluster around the same phases of the month, the same periods of stress, or for no obvious reason at all.
Hormonal acne in women is a well-characterized medical condition with a documented pathophysiology, evidence-based treatment options, and increasingly clinical guidelines that dermatologists can use to match the right intervention to the right patient. In Canada, where access to prescribing physicians and dermatologists varies significantly by region, understanding what is actually happening in the skin makes a meaningful difference to the decisions a woman can make with her doctor, and to what she can reasonably address in the meantime.
This article covers what the research says about why hormonal acne happens in adult women, what the best-supported treatment options are, and how to build a skincare routine around the evidence
What Is Hormonal Acne, and Why Does It Happen in Adult Women?
Acne is fundamentally a disease of the pilosebaceous unit, which is the hair follicle and its associated sebaceous (oil) gland. In adult women, the most consistent upstream driver of that disease is androgenic hormonal activity. Androgens, the group of hormones that includes testosterone, dihydrotestosterone (DHT), and dehydroepiandrosterone sulfate (DHEAS), stimulate sebaceous glands to produce more sebum and create the follicular hyperkeratinization that traps it. When those two combine in the right environment, the Cutibacterium acnes (C. acnes) bacteria proliferate, and an inflammatory lesion follows.
What makes adult female acne distinct, making it confusing for so many women, is that elevated androgen levels in the bloodstream are not always required. A significant proportion of women with hormonally driven acne have normal serum androgen levels when tested. The acne appears because of one of two compensating mechanisms: either increased local 5α-reductase activity at the skin level, which converts circulating testosterone into the significantly more potent DHT directly within the sebaceous gland, or heightened androgen receptor density in acne-prone areas, which makes the skin more sensitive to whatever androgens are circulating, regardless of their absolute concentration.
This explains a clinical reality that surprises many women: you can have hormonal acne with perfectly normal bloodwork.
Persistent versus late-onset acne. Clinically, adult female acne is classified into two patterns. Persistent acne continues from adolescence into adulthood, and this form is more frequently associated with polycystic ovary syndrome (PCOS), irregular menstrual cycles, hirsutism, and biochemical hyperandrogenemia. Late-onset acne, on the other hand, begins after age 25 with no prior history, and may have more multifactorial drivers such as stress, diet, medications, or local androgen sensitivity without systemic hormonal elevation. Both patterns warrant evaluation, but persistent acne with other signs of androgen excess has the stronger indication for systemic hormonal assessment.
Where the Androgens Come From
Understanding the sources of androgen excess in women matters clinically because the right treatment depends partly on where the androgenic drive originates.
Ovarian androgens and PCOS. PCOS is the most common cause of hyperandrogenism in reproductive-age women, affecting between 6 and 15% of this group. In PCOS, chronically elevated luteinizing hormone (LH) and hyperinsulinemia together drive excess testosterone production from the ovarian theca cells. It is the dominant syndrome linking acne, elevated free testosterone, and metabolic features like insulin resistance, and one cohort review found that the majority of hyperandrogenic adult female acne cases could be traced to it.
Adrenal androgens. DHEAS and 17-hydroxyprogesterone are the primary adrenal androgen markers. Elevated DHEAS has been independently associated with acne presence and severity in women with PCOS, and adrenal contribution is particularly worth considering in women whose acne is accompanied by fatigue, stress responsiveness, or a pattern that worsens sharply in high-demand periods.
Peripheral conversion and insulin resistance. Adipose tissue, skin, and liver can convert precursor hormones such as DHEA and androstenedione into active androgens through AKR1C3 enzyme, a process that is upregulated in obesity and PCOS. This peripheral pathway is often overlooked in clinical evaluation but helps explain why metabolic factors like insulin resistance amplify androgenic acne even when ovarian and adrenal production are not markedly elevated.
The insulin connection. Insulin resistance deserves its own mention because it functions as a hormonal amplifier across multiple pathways simultaneously. Hyperinsulinemia stimulates both ovarian and adrenal androgen production, suppresses hepatic SHBG synthesis (which increases the amount of free, biologically active testosterone), and activates insulin-like growth factor 1 (IGF-1), which in turn enhances 5α-reductase activity and sebocyte lipogenesis. A study of 305 women with PCOS found that a 2-hour glucose reading above 140 mg/dL was an independent predictor of acne severity, with an odds ratio of 3.25. Metabolic health and hormonal acne are not separate conversations.
What to test and when. When a dermatologist or physician evaluates adult female acne with hormonal features, standard laboratory assessment typically includes total and free testosterone, DHEAS, androstenedione, SHBG, prolactin, and cortisol. These are ideally measured in the early follicular phase of the menstrual cycle (days 2–5) for the most reliable interpretation. One large adult cohort study found clinical signs of hyperandrogenism in 71.7% of women assessed, but biochemical hyperandrogenemia in only 18.3%, reinforcing that laboratory testing, while useful, is not the only or even primary indicator for hormonal treatment.
The clinical features that most reliably suggest referral for hormonal evaluation include irregular menses, hirsutism (excess hair growth in androgen-sensitive areas), female-pattern hair loss, significant acne that is late-onset or treatment-resistant, obesity, signs of metabolic syndrome, or infertility.
How Hormonal Acne Behaves Differently
The pattern of hormonal acne in adult women is usually different enough from teenage acne to be clinically distinguishable. It tends to concentrate in the lower third of the face in spots like the jawline, chin, and lower cheeks. This is because these areas have the highest androgen receptor density and 5α-reductase activity of any facial skin. It tends to flare predictably in the week before menstruation, when progesterone surges and estrogen drops, shifting the hormonal balance toward relative androgen dominance. It often presents as deep, tender nodular lesions rather than surface whiteheads, because the androgenic stimulus is happening at the level of the sebaceous gland rather than primarily at the follicular opening. And it tends to be stubborn to topical-only treatment, because the upstream hormonal driver is still active.
None of this means topical care is irrelevant it is an important part of management for most women. It means topical care alone is frequently insufficient when the hormonal driver is significant and ongoing.
Evidence-Based Treatments: Hormonal Options
Combined oral contraceptives (COCs) are conditionally recommended by the 2024 American Academy of Dermatology (AAD) guidelines for both inflammatory and non-inflammatory acne in women. Their anti-androgenic mechanism is well-characterized: COCs suppress ovarian androgen production, increase SHBG (which reduces free testosterone), and decrease 5α-reductase activity. A meta-analysis of 32 randomized controlled trials demonstrated a 62% reduction in inflammatory lesions at 6 months with COC use — comparable to the 58% reduction seen with oral antibiotics. Four COC formulations carry FDA approval for acne specifically, though most third- and fourth-generation formulations with antiandrogenic progestins are broadly effective. An important caution: progestin-only formulations (the "mini-pill") may worsen acne due to androgenic properties and should not be chosen for this indication. Thromboembolic risk, particularly in women who smoke, have migraines, or have hypertension, must be weighed individually. Clinical improvement typically requires three to six months of consistent use, which means COCs are a long-term commitment, not a short-term solution.
Spironolactone is an antiandrogen and aldosterone antagonist that is conditionally recommended by the AAD and increasingly used as a first-line hormonal option for adult female acne, particularly when PCOS or clinical hyperandrogenism is present. Despite having a more limited RCT base than COCs, multiple retrospective and observational studies demonstrate substantial improvement in female acne, with effectiveness broadly comparable to oral antibiotics. The landmark FASCE randomized trial compared spironolactone directly to doxycycline and found spironolactone more successful by month six, with comparable tolerability. It is typically used at 50–200 mg daily, often in combination with a COC to manage the most common side effects (breast tenderness and menstrual irregularity) and provide contraception, since spironolactone is contraindicated in pregnancy. The hyperkalemia risk widely cited in older prescribing guidance is low in healthy young women, and routine potassium monitoring is no longer recommended by current guidelines for this population.
Clascoterone cream 1% is a newer option that deserves mention because it represents a different approach: a topical androgen receptor inhibitor, the first of its kind approved for acne in patients 12 and older of both sexes. Rather than working systemically, clascoterone competes with DHT for androgen receptor binding directly in the pilosebaceous unit, reducing both sebum production and local inflammatory cytokine synthesis without any systemic antiandrogenic effects. Two phase 3 randomized controlled trials involving 1,440 participants showed significantly greater treatment success versus vehicle at 12 weeks, with a post-hoc analysis finding particularly robust responses in adult women — 23.5% IGA success versus 7.7% for vehicle. The AAD conditionally recommends it, with the conditional status driven by cost rather than efficacy concerns. It is not yet widely available or publicly funded in Canada, but it represents a meaningful option for women who cannot or do not want systemic hormonal therapy.
Evidence-Based Treatments: Non-Hormonal Options
Hormonal therapy addresses the upstream driver of hormonal acne, but it works alongside rather than instead of topical therapy for most patients. The foundation of acne management, regardless of hormonal status, is a topical regimen built on the strongest evidence-based agents.
Topical retinoids (tretinoin, adapalene, tazarotene, trifarotene) are the cornerstone of acne therapy and carry the strongest recommendation in the 2024 AAD guidelines. Their mechanisms — comedolytic (breaking down existing comedones), anti-comedogenic (preventing new formation), and anti-inflammatory — address two of the three primary drivers of acne lesion formation. A large network meta-analysis of 179 randomized controlled trials involving approximately 35,000 patients found that the combination of a retinoid with benzoyl peroxide was the most effective topical approach for mild-to-moderate acne, producing a 26% mean reduction in total lesion count versus placebo. Retinoids also help address the post-inflammatory hyperpigmentation that hormonal acne frequently leaves behind, which is often the most persistent visible consequence for women with darker skin phototypes.
Benzoyl peroxide carries a strong AAD recommendation as a topical antimicrobial with mild comedolytic activity and, crucially, no associated antibiotic resistance — making it the preferred companion to retinoids and antibiotics alike. Topical antibiotics (clindamycin, erythromycin, minocycline) are effective for inflammatory lesions but should not be used as monotherapy, and combining them with benzoyl peroxide is a clinical good-practice standard specifically to prevent resistance development.
Oral antibiotics — doxycycline (strongly recommended), minocycline and sarecycline (conditionally recommended) — are appropriate for moderate-to-severe inflammatory acne in combination with topical therapy, but duration should be limited to reduce the risk of antibiotic resistance. This is one reason hormonal therapies have increasing value for adult women with ongoing hormonal acne: they can provide long-term control without the resistance risk that extended antibiotic use creates.
Isotretinoin remains the most effective treatment available for severe, scarring, or treatment-refractory acne. The AAD issues a good practice statement for its use in these settings. A cumulative dose of 120–150 mg/kg is the standard target for reducing relapse. For women specifically, the teratogenicity of isotretinoin makes enrollment in appropriate monitoring programs mandatory, along with reliable contraception during and for one month after treatment.
Where Skincare Fits In: Building a Routine Around Hormonal Acne
Over-the-counter skincare is not a substitute for medical management of significant hormonal acne, and it is important to be clear about that. But it is a meaningful supporting layer — both in terms of what it can do directly and in terms of what it avoids doing that would worsen a skin barrier already challenged by the inflammatory process of active acne.
The cleanser matters more than most people think. The instinct for acne-prone skin is often to cleanse aggressively, sometimes multiple times a day, using strong foaming formulas intended to strip oil. This approach reliably worsens acne by disrupting the skin barrier and triggering compensatory sebum production. A non-stripping, pH-balanced cleanser that removes buildup without compromising the lipid layer is what the evidence supports. The Kale Face Cleanser was formulated with this principle: plant-derived mild surfactants, barrier-supporting kale protein, and aloe vera and green tea to soothe, rather than provoke, already-reactive skin.
Niacinamide is the most relevant over-the-counter active for hormonal acne. It reduces inflammatory cytokine signaling in sebaceous glands, regulates sebum production, strengthens the skin barrier — which is frequently compromised in active acne — and addresses the post-inflammatory hyperpigmentation that hormonal breakouts reliably leave behind. Critically, niacinamide does this without the irritation risk that makes many other actives counterproductive during periods of active inflammation. For a Canadian woman managing hormonal acne while working with her physician on systemic options, a niacinamide-forward serum is genuinely useful, not just supportive. The Niacinamide + Vitamin C Brightening & Pore-Refining Serum combines niacinamide with a stable vitamin C derivative and panthenol — directly relevant to both the inflammatory phase of active hormonal acne and the pigmentation repair that follows.
Hydration without occlusion. Active acne does not mean the skin doesn't need moisture. Barrier compromise from acne and its treatments — particularly retinoids and benzoyl peroxide — actually increases the importance of regular, non-comedogenic moisturization. The Lightweight Daily Moisturizer with Hyaluronic Acid & Niacinamide absorbs without adding grease or occluding follicles, and its built-in niacinamide continues the anti-inflammatory and sebum-regulating work of the serum step throughout the day.
Exfoliation: useful, but carefully. Salicylic acid (BHA) is the most follicle-specific exfoliant available over the counter, penetrating the pore to address the hyperkeratinization that underpins comedone formation. It is a genuinely useful addition for acne-prone skin, used two to three times weekly rather than daily, and avoiding the period immediately after starting any retinoid. The Resurfacing Face Serum with Glycolic Acid & AHA Complex contains both glycolic acid and salicylic acid alongside aloe vera and hyaluronic acid to buffer irritation — appropriate for texture and follicular maintenance between retinoid or prescription treatment, not a simultaneous combination with prescription-strength actives.
For a detailed comparison of how salicylic acid and glycolic acid work differently for acne and pores, see Salicylic Acid vs Glycolic Acid: Which Is Better for Acne, Pores & Dark Spots? A Doctor-Reviewed Guide (Canada 2026).
If you are also navigating stress as a driver of your breakouts — and many women with hormonal acne are — see Stress Acne, Hair Loss & Premature Aging: What a Doctor Wants Canadians to Know (2026) for the research on how the HPA axis connects stress to sebaceous gland activity directly.
What to Avoid
Harsh, stripping cleansers and over-cleansing. The most common well-intentioned mistake in hormonal acne management. Stripping the barrier increases TEWL, triggers compensatory sebum production, and makes the skin simultaneously more oily and more reactive — exactly the wrong direction.
Expecting topical-only treatment to fully resolve hormonally-driven acne. Topical agents address the lesion; they do not address the sebaceous hyperstimulation happening upstream. For women whose acne has a genuine hormonal pattern — predictable premenstrual flaring, jawline and chin concentration, deep cystic lesions — the evidence supports involving a physician for hormonal evaluation and, where appropriate, systemic treatment.
Self-treating with over-the-counter hormonal supplements without medical oversight. Products marketed to "balance hormones" or reduce androgens naturally are widely available but have limited and generally low-quality evidence. More importantly, they are being applied to a condition that may have underlying causes — PCOS, adrenal dysfunction, insulin resistance — that need to be properly diagnosed and monitored. Self-treatment that masks symptoms without addressing the cause can delay appropriate management.
Multiple actives used simultaneously. Combining a retinoid, benzoyl peroxide, a salicylic acid exfoliant, and a strong vitamin C serum in the same evening routine on sensitized, acne-inflamed skin creates a cumulative barrier disruption that outpaces the benefit of any individual ingredient. With prescription acne therapy in particular, over-the-counter active use should be discussed with the prescribing clinician rather than layered on independently.
Ignoring post-inflammatory hyperpigmentation until it becomes deeply set. The darkening that follows a hormonal breakout is not permanent scar tissue — it is melanin-based discolouration that responds well to early, consistent treatment with niacinamide, vitamin C, and daily SPF. Waiting months to address it makes the treatment timeline meaningfully longer.
For guidance on introducing retinoids into a skin routine that may already involve prescription acne therapy, see Retinol for Beginners: Safe Start Guide by a Dermatologist (Canada 2026).
Navigating Treatment in Canada
Access to dermatology in Canada is uneven. Wait times for non-emergency dermatology appointments vary substantially by province and can extend to many months in underserved areas. For Canadian women navigating this, a few practical notes are worth making.
Family physicians and nurse practitioners can initiate first-line hormonal and antibiotic acne treatment, including combined oral contraceptives and doxycycline, without specialist referral. Spironolactone for acne is increasingly prescribed at the primary care level and does not require dermatology involvement for most adult women in good health. Isotretinoin does require dermatologist involvement in Canada, as it requires monitoring and informed consent documentation.
When hormonal evaluation is being considered, requesting the full androgen panel — including free testosterone, DHEAS, SHBG, and relevant cycle-phase timing — at a primary care appointment rather than waiting for a dermatologist is a practical way to have information ready when specialist care becomes accessible.
Expert Opinion
In my clinical experience, the most important shift in how adult female acne is understood is the recognition that it is frequently an endocrine condition expressing at the skin level, not a skin condition with occasional hormonal features, and that reframing changes how both physicians and patients approach it. The pathophysiology is well-established: local 5α-reductase activity and androgen receptor density in the lower facial pilosebaceous units drive the jawline and chin predominance and the premenstrual flare pattern that identifies hormonal acne even when serum androgens are entirely normal, because the relevant biochemistry is happening within the skin itself rather than just in the circulation. The current evidence supports a stepwise approach in which topical retinoids and benzoyl peroxide provide the anti-comedogenic and anti-inflammatory foundation, while hormonal therapy combined oral contraceptives or spironolactone, or both addresses the upstream sebaceous hyperstimulation that topicals cannot reach; the FASCE trial finding that spironolactone outperformed doxycycline by month six is a meaningful clinical signal that hormonal therapy deserves earlier consideration for women with a clear hormonal pattern, rather than being reserved for those who have already cycled through antibiotics. For the skincare side of management, realistic expectation-setting is essential: niacinamide is genuinely useful for its anti-inflammatory and sebum-regulating properties and for addressing the post-inflammatory pigmentation that follows hormonal breakouts, but no over-the-counter serum addresses the androgen-receptor mediated sebocyte hyperstimulation that underlies the condition in the first place. My practical recommendation for Canadian women is to document the pattern — timing relative to the menstrual cycle, lesion location and morphology, and the presence of any other androgenic features — bring that picture to a physician, and build the skincare routine around supporting the medical treatment rather than replacing it.
The Bottom Line
Hormonal acne in adult women is common, well-characterized, and treatable, but it requires a clear-eyed understanding of what is actually driving it. Androgens, whether from ovarian, adrenal, or peripheral sources, stimulate the pilosebaceous unit to produce more sebum and accelerate the follicular changes that produce breakouts. In many women, that drive happens at the level of local androgen receptor sensitivity rather than through elevated bloodwork, which is why "normal" hormone tests don't rule out hormonal acne.
The most evidence-supported treatment combines a topical foundation retinoid, benzoyl peroxide, and non-comedogenic moisturizer with systemic hormonal therapy when the pattern warrants it. Spironolactone and combined oral contraceptives have strong clinical evidence. Isotretinoin remains the most effective option for severe or refractory disease. Over-the-counter skincare, particularly niacinamide-based serums and barrier-first formulations, plays a meaningful supporting role in managing inflammation, reducing post-acne pigmentation, and maintaining the barrier integrity that both the disease and its treatments can compromise. It is not, on its own, the solution to a condition rooted in androgenic hormonal biology.
References
Zaenglein, A.L., et al. Guidelines of care for the management of acne vulgaris: 2024 update. Journal of the American Academy of Dermatology. 2024.
Carmina, E., et al. Androgen excess in adult women: clinical features, endocrine evaluation, and dermatologic implications. Gynecological Endocrinology. 2022.
Amuzescu, A., et al. Hormonal drivers of adult female acne: ovarian, adrenal, peripheral, and metabolic contributions. Romanian Journal of Dermatology. 2024.
Da Rocha, M., et al. Adult female acne and hyperandrogenism: clinical-biochemical correlation and treatment implications. International Journal of Dermatology. 2024.
Smith, K.A., et al. Androgen-mediated sebaceous gland activity in adult female acne: sebocyte biology and clinical relevance. Dermatology. 2025.
Borzyszkowska, D., et al. Polycystic ovary syndrome as the dominant systemic association in adult female acne: pathophysiological review. Journal of Clinical Medicine. 2022.
Damoulaki, A., et al. PCOS, free testosterone, and insulin resistance as determinants of acne severity in reproductive-age women: a systematic review. Hormones (Athens). 2025.
Sardana, K., et al. Clinical hyperandrogenism versus biochemical hyperandrogenemia in adult female acne: a large cohort analysis. Indian Dermatology Online Journal. 2020.
Kim, J.E., et al. Clinical clues for endocrine evaluation in adult female acne: when to test and what to test for. Journal of the American Academy of Dermatology. 2024.
Del Rosso, J.Q., et al. Anti-androgenic mechanisms of combined oral contraceptives and topical antiandrogens in sebaceous gland biology. Journal of Clinical and Aesthetic Dermatology. 2024.
Dréno, B., et al. FASCE randomized trial: spironolactone versus doxycycline for adult female moderate acne — 6-month outcomes. British Journal of Dermatology. 2024.
Tommasino, N., et al. Hormonal acne in women: when to choose hormonal therapy and how to integrate it with standard topical management. Journal of the European Academy of Dermatology and Venereology. 2025.
Reynolds, R.V., et al. Evidence-based management of acne vulgaris: network meta-analysis of 179 RCTs including topical, oral, and isotretinoin regimens. JAMA Dermatology. 2024.
Leung, A.K.C., et al. Topical retinoids and benzoyl peroxide as cornerstone acne therapy: review of evidence and clinical application. Skin Therapy Letter. 2021.
Patiyasikunt, M., et al. Placebo-controlled trial of spironolactone 50 mg plus benzoyl peroxide in moderate adult female acne. Dermatologic Therapy. 2020.
Del Rosso, J.Q., et al. Clascoterone 1% cream as a topical androgen receptor inhibitor: mechanism of action and phase 3 RCT evidence in adult women. Journal of Drugs in Dermatology. 2024.
Elnagar, A.M., et al. Isotretinoin in women with acne and PCOS: preliminary evidence of reduced free testosterone following treatment. Endocrine Practice. 2024.
Mohammad, T.F., et al. Antibiotic resistance in acne management: rationale for hormonal alternatives and duration-limited antibiotic use. Dermatology and Therapy. 2025.
Amuzescu, Andreea, M. Tampa, C. Matei, and S. Georgescu. "Adult Female Acne: Recent Advances in Pathophysiology and Therapeutic Approaches." Cosmetics (2024).
Borzyszkowska, Dominika, M. Niedzielska, M. Kozłowski, A. Brodowska, Adam Przepiera, Kinga Malczyk-Matysiak, A. Cymbaluk-Płoska, and E. Sowińska-Przepiera. "Evaluation of Hormonal Factors in Acne Vulgaris and the Course of Acne Vulgaris Treatment with Contraceptive-Based Therapies in Young Adult Women." Cells 11 (2022).
Brănișteanu, D., M. Toader, E. Porumb, I. Șerban, A. Pînzariu, Cătălina Ioana Brănişteanu, Ana Vicovan, et al. "Adult female acne: Clinical and therapeutic particularities (Review)." Experimental and Therapeutic Medicine 23 (2021).
Carmina, E., B. Dréno, W. A. Lucky, W. G. Agak, A. Dokras, J. Kim, R. Lobo, F. Ramezani Tehrani, and D. Dumesic. "Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee." Journal of the Endocrine Society 6 (2022).
Da Rocha, M. Dias A., M. Saint Aroman, Valerie Mengeaud, Fabienne Carballido, G. Doat, A. Coutinho, and E. Bagatin. "Unveiling the Nuances of Adult Female Acne: A Comprehensive Exploration of Epidemiology, Treatment Modalities, Dermocosmetics, and the Menopausal Influence." International Journal of Women's Health 16 (2024): 663 - 678.
Damoulaki, Eftichia, D. Sioutis, Vaia Sarli, Eutychios Trakakis, G. Mastorakos, Alexander Katoulis, Konstantinos Kastrinakis, et al. "Polycystic Ovary Syndrome-Associated Acne: The Interplay of Hyperandrogenism, Insulin Resistance, and Therapeutic Strategies." Cureus 17 (2025).
Del Rosso, James Q, and L. Kircik. "The cutaneous effects of androgens and androgen-mediated sebum production and their pathophysiologic and therapeutic importance in acne vulgaris." Journal of Dermatological Treatment 35 (2024)..
Dréno, B., Jean-Michel Nguyen, E. Hainaut, L. Machet, M. Leccia, N. Bénéton, J. Claudel, et al. "Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study." Acta Dermato-Venereologica 104 (2024).
Elnagar, Heba, Osama A. Hashem, Hany O Aboelwafa, E. ELhelw, and M. Elsaie. "The impact of oral isotretinoin on ovarian functions of acne patients complaining of polycystic ovarian syndrome: a prospective study." Journal of Ovarian Research 17 (2024). .
Gayen, R., I. Podder, I. Chakraborty, and S. Chowdhury. "Sex Hormones, Metabolic Status, and Obesity in Female Patients with Acne Vulgaris Along with Clinical Correlation: An Observational Cross-Sectional Study." Indian Journal of Dermatology 66 (2021): 60 - 66.
Kim, Hyun Jee, and Y. Kim. "Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies." International Journal of Molecular Sciences 25 (2024).
Leung, Alexander K. C., B. Barankin, J. Lam, K. Leong, and K. Hon. "Dermatology: how to manage acne vulgaris." Drugs in Context 10 (2021).
Lonardo, M., N. Cacciapuoti, B. Guida, M. Di Lorenzo, M. Chiurazzi, Simona Damiano, and C. Menale. "Hypothalamic-Ovarian axis and Adiposity Relationship in Polycystic Ovary Syndrome: Physiopathology and Therapeutic Options for the Management of Metabolic and Inflammatory Aspects." Current Obesity Reports 13 (2024): 51 - 70.
Mohammad, Pour A., and G. Bae. "A Cross-Sectional Study Analyzing Recent Trends in the Treatment of Acne Vulgaris: Prescription Patterns and Demographic Data From the 2018-2019 National Ambulatory Medical Care Survey (NAMCS) Database." Cureus 17 (2025).
Patiyasikunt, Mattana, Bussabong Chancheewa, P. Asawanonda, N. Noppakun, and C. Kumtornrut. "Efficacy and tolerability of low‐dose spironolactone and topical benzoyl peroxide in adult female acne: A randomized, double‐blind, placebo‐controlled trial." The Journal of Dermatology 47 (2020).
Poinas, A., M. Lemoigne, Sarah Le Naour, J. Nguyen, S. Schirr-Bonnans, V. Riche, Florence Vrignaud, et al. "FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial." Trials 21 (2020).
Reynolds, R., Howa Yeung, Carol E. Cheng, F. Cook-Bolden, S. Desai, Kelly Druby, E. Freeman, et al. "Guidelines of care for the management of acne vulgaris.." Journal of the American Academy of Dermatology (2024).
Sardana, K., Prekshi Bansal, Lokesh Sharma, U. C. Garga, and Gauri Vats. "A study comparing the clinical and hormonal profile of late onset and persistent acne in adult females." International Journal of Dermatology 59 (2020).
Smith, Courtney A, E. Gosnell, Turkan Banu Karatas, C. Deitelzweig, Elizabeth Collins, and Howa Yeung. "Hormonal Therapies for Acne: A Comprehensive Update for Dermatologists." Dermatology and Therapy 15 (2025): 45 - 59.
Tommasino, Nello, M. C. Annunziata, L. Potestio, and M. Napolitano. "Efficacy and Safety of Hormonal Therapies for Acne: A Narrative Review." Clinical, Cosmetic and Investigational Dermatology 18 (2025): 3331 - 3337.
